Senesco Technologies Reports Results of Preclinical Animal Sepsis Study
30 April 2005
Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) reported today that mice treated with Senesco's proprietary technology have shown a marked survival benefit in the lethal sepsis study conducted at the University of Virginia (Charlottesville, VA) by Dr. W. Michael Scheld. Sepsis is a condition in which the immune system's rapid inflammatory response to a severe infection can cause organ damage and result in death and is the leading cause of death in non-coronary intensive care units in the United States.
The study was conducted using a mouse model for sepsis and was designed to test Senesco's Factor 5A inhibition technology's ability to protect septic mice from death using different dosing schedules. In this model, for groups that received Senesco's Factor 5A inhibitor, survival ranged from 20% to 100% of the mice, depending upon mouse strain and dosing regime. None of the untreated mice survived.
John E. Thompson, Ph.D., Senesco's executive vice president and chief scientific officer commented, "We were pleased to see that our Factor 5A inhibitor was able to increase survival in an animal model of lethal septic challenge. We look forward to the next phase of this study."
W. Michael Scheld, M.D., professor of internal medicine, noted, "A great deal of work needs to be done, particularly in understanding the mechanism of action. However, these preliminary data are very encouraging."
About Senesco Technologies, Inc.
Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates cell life. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has undertaken preclinical research in certain areas of human health.
Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco partners with leading-edge companies and earns research and development fees for applying its technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and utilizes research laboratories at universities and research centers throughout North America.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the success and timing of the Company's studies and preclinical trials; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
--------------------------------------------------------------------------------
Contact:
Senesco Technologies, Inc.
Bruce Galton, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
Source: Business Wire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|
